4 results
Investigate the activity and safety of amrubicin alone versus amrubicin incombination with cisplatin versus standard treatment for extensive disease(ED) small-cell lung cancer in the first line setting.
The primary objective is the Objective tumor response rate (RECIST). Secondary objectives are: duration of overall response, time to tumor progression (TTP), progression free survival (PFS), overall survival, toxicity profile, incidence of…
Primary objectives:Phase 1b:Arm A (BGB-290 + radiation therapy [RT]): Subjects with first-line glioblastoma (GB) with unmethylated MGMT promoter (*unmethylated GB*)• To assess safety and tolerability of BGB-290 combined with RT• To identify dose-…
To investigate the effect of oral magnesium supplementation on insulin sensitivity in people with T2DM and a low serum magnesium concentration.